Eurobench.com

[verwijderd] 24 oktober 2007 15:55

0

King Pharmaceuticals to Cut Costs, 20 Percent of Work Force

BRISTOL, Tenn. -- King Pharmaceuticals announced today actions it is taking to accelerate a planned strategic shift, emphasizing its focus in neuroscience and hospital/acute care to maximize its long-term growth. The Company is taking these actions, which include a workforce reduction of approximately 20% and other general and administrative expense decreases, in light of recent challenges to its ALTACE® (ramipril) franchise. King expects to realize the full benefit of these initiatives commencing in 2008. The Company estimates that the 2008 cost savings from these actions will range from $75 million to $90 million.

In September 2007, the U.S. Court of Appeals ruled against the continued validity of the patent covering King’s ALTACE® product. The Company has filed a petition with the court seeking reconsideration of the decision, asserting it involves significant errors.

Brian A. Markison, Chairman, President and Chief Executive Officer of King, stated, “In light of last month’s decision and the uncertainty that it creates with respect to the future of our ALTACE® franchise, we are accelerating our plan to sharpen our focus on neuroscience and hospital/acute care. This strategic shift was initiated several years ago in anticipation of the eventual loss of ALTACE® exclusivity.”

“King’s existing platforms in neuroscience and hospital/acute care and aggressive business development initiatives position the Company to effectively capitalize on the positive dynamics of both marketplaces. As a result, we are now in the process of realigning our organization and optimizing the Company’s cost structure, which primarily involves restructuring the size and focus of our sales force to better support the priorities of our strategic plan,” explained Mr. Markison.

Mr. Markison added, “Our restructuring plan also takes into consideration our cardiovascular/metabolic assets, and we intend to honor our existing commitments with respect to ALTACE® and GLUMETZA™ (metformin hydrochloride extended-release tablets).”

In recent years, King has developed a strong pain management franchise, which includes existing products like SKELAXIN® (metaxalone) and AVINZA® (morphine sulfate extended release) as well as products in development like REMOXY™ (long-acting oral oxycodone). In the hospital/acute care area, King’s portfolio of products is led by THROMBIN-JMI® (thrombin, topical, bovine, USP) and its recently added line extensions and the Company’s auto-injector products, which include EPIPEN® (epinephrine).

“We believe the expense reduction measures announced today will enable us to continue generating strong cash flow to invest in our pipeline and business development opportunities, further strengthening our neuroscience and hospital/acute care platforms,” said Joseph Squicciarino, Chief Financial Officer of King Pharmaceuticals.

King’s cash flow from continuing operations for the first six months of 2007 totaled approximately $253 million, with cash, cash equivalents and investments in debt securities equaling $923 million as of June 30, 2007.

“We remain committed to expanding our product portfolio through investing in R&D, acquiring exciting late-stage compounds and continuing as a partner of choice for promising products and technologies,” concluded Mr. Markison.

King will incur special charges during 2007 of approximately $150 million to recognize the impaired value of its intangible assets associated with ALTACE® and approximately $90 million primarily related to the impaired value of raw material inventory and related contracts associated with ALTACE®. King estimates that it will also incur a one time charge of approximately $70 million during 2007 related to the restructuring announced today.

The Company plans to provide more details with respect to today’s announcement during its conference call on November 8, 2007, the date it intends to announce its financial results for the third quarter ended September 30, 2007.

Ruud..

[verwijderd] 25 oktober 2007 00:06

0

Jury Rules Roche Infringes Amgen's EPO Patents

THOUSAND OAKS, Calif. -- Oct. 23, 2007--Amgen announced today that a jury in the U.S. Federal District Court in Boston ruled that Roche's pegylated-erythropoietin (peg-EPO) product MIRCERA infringes 11 Amgen EPO patent claims.

Amgen is pleased with the jury's verdict and will now seek an injunction to prevent Roche from commercializing its peg-EPO product in the United States in violation of Amgen's affirmed patent rights. The injunction hearing is scheduled for Nov. 15, 2007.

In addition to infringing its EPO patents, Amgen firmly believes Roche's peg-EPO product provides no clinical or patient benefit over Amgen's innovative therapies, EPOGEN(R) (Epoetin alfa) and Aranesp(R) (darbepoetin alfa).

Amgen remains committed to investing in innovative research and to delivering medicines that treat grievous illness and meet unmet medical needs.

About Amgen

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

Ruud..

[verwijderd] 25 oktober 2007 00:07

0

The axe is about to fall at GlaxoSmithKline. The drug maker reported a 5.8 percent drop in profits to $2.77 billion--partly due to generic competition, but largely from a 48 percent slide in Avandia sales. Next: A three-year, $1.4 billion cost-saving plan that will include job cuts.

From whence might those cuts come? Avandia's sales force, for starters, or so company sources have been saying. London's Times newspaper reports that Glaxo has been waiting to decide about the sales team until the FDA finalizes safety warnings on Avandia's product label.

Well, now we know what the FDA wants. The Wall Street Journal reports that the agency is pushing Glaxo toward a "black box" warning of increased heart attack risk. Avandia already carries a black box about heart-failure risk; pointing out heart-attack dangers would be another blow to its fortunes.

Ruud..

[verwijderd] 25 oktober 2007 00:09

0

Panel Recommends FluMist for Young Kids
By MIKE STOBBE, AP Medical Writer

Wednesday, October 24, 2007

Printable VersionEmail This Article del.icio.us
Digg
Technorati
Reddit Slashdot
Fark
Newsvine
Google Bookmarks
(0) Georgia (default)
Verdana
Times New Roman
Arial

Back to Health

(10-24) 13:46 PDT ATLANTA (AP) --

Children as young as 2 can be given a nasal spray flu vaccine, a federal advisory panel said Wednesday.

Government advice now recommends only traditional shots for children younger than 5. But recent studies have shown the vaccine FluMist, made by Maryland-based MedImmune Inc., to be safe and effective in kids as young as 2.

FluMist was initially approved in 2003 for use in healthy people ages 5 to 49. The U.S. Food and Drug Administration last month approved its use for the 2 to 5 age group as well.

Now, the Advisory Committee on Immunization Practices, which advises government health officials, is recommending FluMist's use for kids in the 2 to 5 age bracket. Committee members said Wednesday that children with a history of asthma or wheezing should opt for a shot.

Recommendations by the panel usually are accepted by U.S. health officials, and they influence insurance companies' decisions on vaccination coverage.

The committee didn't recommend FluMist over flu shots, merely making it an option for young children who may dread a shot with a needle. Flu shots are still recommended for children ages 6 months to 5 years and those 50 and over as well as other groups at risk for flu complications.

The committee also voted that a government program that pays for vaccines extend its FluMist coverage to the younger age group, meaning more than 5 million children will now be eligible for free FluMist. That includes children eligible for Medicaid, members of Native American and Alaska Native groups, and some children who don't have insurance that covers the vaccination.

"This is a significant step forward in our vision to have a significant impact on influenza disease in all age groups," said Frank Malinoski, MedImmune's senior vice president for medical and scientific affairs.

MedImmune is a wholly owned subsidiary of London-based AstraZeneca PLC. The company had $36 million in FluMist sales last year, and has made about 4.5 million doses for the current flu season, a company spokeswoman said.

A dose of FluMist costs about $18, roughly the cost of a flu shot. One dose is recommended annually, but if it's the first time a young child was ever vaccinated against flu, two doses should be given, spaced at least a month apart.

The committee also discussed a proposal to recommend flu vaccinations for all school-age children.

Health officials believe vaccinating more children would reduce the spread of flu in general as well as protecting the students themselves. But experts say they're concerned about the strain on pediatricians and schools if they tried to give annual flu shots to so many children.

The discussion was tabled until the committee's next meeting in February.

Ruud..

[verwijderd] 25 oktober 2007 00:25

0

www.fiercebiotech.com/press-releases/...

Erg leerzaam.
Ook een mooi partner?

Ruud..

[verwijderd] 25 oktober 2007 10:10

0

Beste mensen,

Heeft iemand enig info wanneer de eu goedkeuring nu ongeveer verwacht wordt.Zoveel onzin draadjes op de forum dat ik helaas niet door alles heen kan lezen.
Aub een sereuz antwoord.Ik heb er 7 k staan en zonder info moet ik toch dumpen met verlies denk ik.

alvast mijn dank,

[verwijderd] 25 oktober 2007 10:13

0

quote:
guvea schreef:
Heeft iemand enig info wanneer de eu goedkeuring nu ongeveer verwacht wordt.Zoveel onzin draadjes op de forum dat ik helaas niet door alles heen kan lezen.

12-17 november CHMP meeting. Waarschijnlijk wordt daar de zegen gegeven aan Rhucin.

[verwijderd] 25 oktober 2007 10:15

0

quote:
guvea schreef:
Beste mensen,

Heeft iemand enig info wanneer de eu goedkeuring nu ongeveer verwacht wordt.Zoveel onzin draadjes op de forum dat ik helaas niet door alles heen kan lezen.
Aub een sereuz antwoord.Ik heb er 7 k staan en zonder info moet ik toch dumpen met verlies denk ik.

alvast mijn dank,

Nee! Niemand heeft enig idee, zo is het maar! verwacht kan worden dat een van de twee meetings uitsluitsel gaat geven.
DWZ November of December.
Kijk op onderstaande URL voor de data.

www.emea.europa.eu/

Ruud.. Succes en sorrie het is niet anders

[verwijderd] 25 oktober 2007 10:40

0

Dankjewel Ruud en Pharmer,

Mijn verwachting is ook medio november.Ik ging voor short maar wordt toch midlong zo te zien.Er is tenminste iets om op te wachten om het verlies te beperken.

Succes,

[verwijderd] 25 oktober 2007 11:44

0

quote:
guvea schreef:
Dankjewel Ruud en Pharmer,

Mijn verwachting is ook medio november.Ik ging voor short maar wordt toch midlong zo te zien.Er is tenminste iets om op te wachten om het verlies te beperken.

Succes,

svp nokkuh met dat geouwehoer en puur info posten!

[verwijderd] 25 oktober 2007 11:45

0

www.canadianbusiness.com/markets/head...

Dyax's Loss Widens As Costs Rise to Develop Rare Blood Disease Treatment, Revenue Declines

October 24, 2007 - 3:14 p.m.

CAMBRIDGE, Mass. (AP) - Drug developer Dyax Corp. said Wednesday its third-quarter loss widened on higher costs for its DX-88 hereditary angioedema treatment candidate and lower revenue.

Hereditary angioedema is a potentially fatal genetic disorder involving a deficiency of a certain type of protein in blood plasma.

Dyax posted a loss of $15.3 million, or 26 cents per share, compared with a loss of $11.5 million, or 26 cents per share, during the same period a year prior. Revenue fell to $2.6 million from $3.5 million.

The company had about 14.2 million additional shares of stock outstanding for the most recent quarter ending Sept. 30, which accounts for the unchanged loss per share.

Analysts polled by Thomson Financial, on average, expected a loss of 31 cents per share on revenue of $3.3 million.

In February, Dyax assumed responsibility for all development expenses for DX-88 after ending a collaboration with Genzyme. The DX-88 program is delayed because of Food and Drug Administration requests for more data and a new study in order to consider the drug for approval.

Pacific Growth Equities analyst Kimberly Lee said she continues to believe that DX-88 is "the main value driver for the company," and has a "clear path to potential registration" in mid 2008.

The drug is also "an attractive partnering candidate," she said in a note to clients, and "will likely attract a large partnership deal, in our view."

Deutsche Bank analyst Jennifer Chao noted Dyax intends to seek European approval for the drug as well.

Dyax had a total of $73.6 million in cash, cash equivalents, and short-term investments, exclusive of restricted cash, as of Sept. 30. The company said it expects net cash consumption of about $45 million in 2007.

Shares of Dyax fell 12 cents, or 3 percent, to $3.91 in afternoon trading. The stock has traded between $2.85 and $6.95 over the last 52 weeks.

---

tering wat een cijfers! wat een verlies!

[verwijderd] 26 oktober 2007 08:52

0

UCB start fase III onderzoek naar medicijn epilepsie

AMSTERDAM (Dow Jones)--UCB sa begint met fase III van de klinische studies naar brivaracetam, een anti-epilepticum. Dit meldt het Belgische farmaceutische bedrijf vrijdag voorbeurs.

UCB verwacht in het derde kwartaal van 2009 de eerste resultaten van de studie naar het medicijn, dat de commerciele naam Rikelta zal dragen.

"Tot 30% van de patienten vertoont nu resistentie tegen de huidige anti-epileptische middelen en UCB wil aan deze bestaande medische nood tegemoet komen", aldus hoofd ontwikkeling Iris Low-Friedrich van UCB.

Door Anna Marij van der Meulen, Dow Jones Nieuwsdienst; +31-20-5890270, annamarij.vandermeulen@dowjones.com

[verwijderd] 29 oktober 2007 11:46

0

Published: 11:08 29.10.2007 GMT+1 /HUGIN /Source: Jerini AG /GER: JI4 /ISIN: DE0006787476

Jerini Submits New Drug Application for Icatibant in the Treatment of HAE to the FDA and Requests Priority Review

Berlin, October 29, 2007 - Jerini AG (FSE:JI4) announced today the submission of its electronic New Drug Application (NDA) for Icatibant in the treatment of hereditary angioedema (HAE) to the US Food and Drug Administration (FDA) as well as the company's request for priority review. Jerini has received technical clearance of its eCTD (Electronic Common Technical Document) from the agency, which ensures that the documentation meets the agency's technical standards. The FDA has up to 60 days to determine whether the application is complete and meets the regulatory requirements for filing. Priority review designation, which shortens the regulatory review period from ten to six months, will also be decided by the agency in this timeframe.

"The NDA submission is a major milestone for Jerini. This important regulatory step in the US along with Icatibant's already accepted European filing demonstrates our commitment to bring this novel treatment to HAE patients in both the US and Europe," said Jens Schneider-Mergener, CEO of Jerini."

About Icatibant
Icatibant, a synthetic peptidomimetic, works by blocking the B2 receptor as an antagonist to the peptide hormone bradykinin. Bradykinin has been shown to be elevated in HAE patients and responsible for edema formation during HAE attacks. Icatibant has been granted orphan drug status for the treatment of angioedema by the US Food and Drug Administration (FDA) and the European Medicines Evaluation Agency (EMEA), potentially securing upon approval, market exclusivity for seven and ten years, respectively. In addition, the FDA has granted fast-track designation to Icatibant in the indication HAE.

About HAE
HAE is a debilitating and potentially life-threatening genetic disease characterized by unpredictable recurring swelling attacks of the hands, feet, face, larynx, and abdomen. It is estimated that approximately 10,000 patients in the United States and Europe have been diagnosed with HAE. HAE attacks affecting the hands, face, and feet can be disfiguring, while attacks in the gastrointestinal tract result in severe pain caused by swelling of the intestinal wall. Attacks that affect the larynx are life-threatening because swelling of the larynx constricts the upper airways and can lead to death by suffocation. The prevalence of HAE is estimated between one in 50,000 and one in 10,000 individuals, and it is estimated that between 15,000 and 75,000 people are affected with HAE in the European Union and the United States.

About Jerini
Jerini is a pharmaceutical company based in Berlin, Germany, focusing on the discovery, development, and commercialization of novel peptide-based drugs. The company pursues disease indications that have limited or no treatment options and has built a drug pipeline composed of its own programs, as well as others in collaboration with established partners. Jerini has completed Phase III clinical trials of Icatibant in the subcutaneous treatment of hereditary angioedema (HAE). The company's marketing authorization application has been accepted for review by the European Medicines Evaluation Agency (EMEA) and granted accelerated assessment by the agency, shortening the regulatory review period from 210 to 150 calendar days. Jerini plans to complete its US submission to the Food and Drug Administration (FDA) in the fourth quarter of 2007. Based on its technology platform, Jerini has also established several in-house development programs, which address indications within the therapeutic areas of ophthalmology, oncology, and inflammatory disease.

ISIN: DE0006787476

For questions, please contact:
Stacy Wiedenmann
Director Investor Relations &
Corporate Communications
Jerini AG
Invalidenstr. 130
10115 Berlin
T + 49 - 30 - 97893 - 285
X + 49 - 30 - 97893 - 599
wiedenmann@jerini.com

Press Release (PDF)

This press release was brought to you by Jerini AG.

voda 29 oktober 2007 18:03

0

Verderop in Europa was het bedrijfsnieuws schaars. Een aantal fondsen profiteerde van advieswijzigingen. Zo dikte het Zwitserse biotechnologiebedrijf Actelion 1,8% aan nadat ING Wholesale banking het advies verhoogde van sell naar hold.

Het Franse Clarins, dat onder meer parfums maakt, profiteerde van een Exane BNP Paribas verhoging van neutral tot outperform. Het aandeel steeg 6,3%.

Harm Luttikhedde
harm@bfn.com

(c) Het Financieele Dagblad in samenwerking met Betten Beursmedia News (contact: webred@fd.nl/ 020-5928456)

[verwijderd] 30 oktober 2007 08:54

0

Organon tekent licentieovereenkomst met Endotis

AMSTERDAM (Dow Jones)--Organon, de biofarmaceutische divisie van Akzo Nobel nv, heeft een exclusieve wereldwijde licentieovereenkomst getekend met Endotis Pharma. Dat meldt het bedrijf dinsdag voorbeurs.

Endotis Pharma, een Frans farmaceutisch bedrijf, gaat voor Organon een aantal stoffen tegen trombose ontwikkelen en verkopen. Er werden geen financiele details bekendgemaakt.

Organon zal door Akzo Nobel voor EUR11 miljard verkocht worden aan het Amerikaanse Schering-Plough. De afronding van de overname wordt eind dit jaar verwacht.

Door Inger Kuin; Dow Jones Nieuwsdienst; +31-20-5890270; inger.kuin@dowjones.com

[verwijderd] 30 oktober 2007 22:00

0

October 30, 2007 - 7:11 AM EDT

Lev Pharmaceuticals Amends Cinryze(TM) BLA to Include Prophylactic Data

Priority Review Designation Targets FDA Action by January 30, 2008 for Both Acute and Prophylactic Indications

Lev Pharmaceuticals, Inc. (“Lev” or the “Company”) (OTCBB:LEVP.OB) today announced the submission of an amendment to its pending Biologics License Application (BLA) for Cinryze™ (C1 inhibitor) for the treatment of hereditary angioedema (HAE), also known as C1 inhibitor deficiency. The amendment includes the data from the Company’s pivotal U.S. Phase III trial of Cinryze™ for the prophylactic treatment of HAE.

As previously announced on October 1, 2007, the FDA accepted for filing the Company’s BLA for Cinryze™ for the acute treatment of HAE and designated the submission for priority review, targeting an FDA action by January 30, 2008. This submission of the prophylactic data will allow the FDA to complete a comprehensive review for both the acute and prophylactic indications of Cinryze™ without affecting the priority review timeline. Priority review status is granted by the FDA to products that, if approved, would be a significant improvement over existing therapies.

“Today’s announcement marks the achievement of another important milestone for Lev,” said Joshua D. Schein, Ph.D., Lev’s Chief Executive Officer. “The submission of the prophylactic data reconfirms our previously stated guidance and potentially moves us one step closer to providing a comprehensive treatment option for HAE patients in 2008," added Schein.

On September 10, 2007, Lev reported positive results from its pivotal U.S. Phase III trial of Cinryze™ for the prophylactic treatment of HAE. In the study, the protocol-defined, pre-specified primary endpoint was achieved, showing a clinically and statistically significant reduction in the number of HAE attacks.

On March, 14 2007, Lev announced the successful completion of its pivotal Phase III clinical trial for the acute treatment of HAE, which demonstrated a clinically and statistically significant reduction in the time to unequivocal relief of acute HAE attacks.

Lev is the only company developing both acute and prophylactic indications for the comprehensive treatment of HAE in the United States.

About Hereditary Angioedema

HAE is a genetic disorder caused by a deficiency of C1 inhibitor, a circulating plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unrestricted, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. While there is no approved therapy for acute HAE attacks in the U.S., C1 inhibitor has been used in Europe to treat HAE for more than 30 years. There are estimated to be 10,000 people with HAE in the United States.

For more information on HAE, visit the U.S. HAE Association’s website at: www.haea.org.

About Lev Pharmaceuticals, Inc.

Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev’s C1 inhibitor, proposed to be marketed as CinryzeTM, has been granted orphan drug status for the treatment and prevention of HAE, potentially securing, upon approval, market exclusivity for seven years. Lev has also received fast track designation status from the FDA, which facilitates the development and expedites the review of drugs and biologics intended to treat serious or life threatening conditions and that demonstrate the potential to address unmet medical needs. Lev is also evaluating the development of C1 inhibitor for the treatment of acute myocardial infarction, or heart attack, and selective other diseases and disorders in which inflammation is known or believed to play an underlying role.

For more information about Lev, C1 inhibitor, or HAE, please contact Lev directly at 212-682-3096, or visit Lev’s website at www.levpharma.com.

Forward Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our plans and objectives of management are forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including risks related to new information arising out of clinical trial results, our heavy dependence on the success of CinryzeTM, our dependence on our suppliers, our dependence on third parties to manufacture CinryzeTM, obtaining regulatory approval to market CinryzeTM; market acceptance of CinryzeTM, maintaining the orphan drug status associated with CinryzeTM, the risks associated with dependence upon key personnel, and our ability to obtain additional funding to support our business activities. These and other risks are described in greater detail in the "Risk Factors that May Affect Results" section of our filings with the SEC. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. We do not assume any obligation to update any forward-looking statements.

Lev Pharmaceuticals, Inc.
Jason Tuthill, 212-850-9130
Director, Investor Relations
jtuthill@levpharma.com

[verwijderd] 31 oktober 2007 10:05

0

Sanofi-Aventis verhoogt outlook dankzij winstgroei in KW3

AMSTERDAM (Dow Jones)--De Franse medicijnproducent Sanofi-Aventis sa verhoogt zijn verwachtingen voor het hele boekjaar 2007, na een duidelijke winststijging in het derde kwartaal. Dit meldt de onderneming woensdag.

Volgens de farmaceut zal de winst per aandeel in 2007 groeien binnen een marge van 10%, waar het bedrijf eerder een marge van 9% inschatte. De winstverwachting is exclusief uitzonderlijke posten.

Daarnaast bevestigt het bedrijf uit te kijken naar farmaceutische acquisities in Japan en een versterking van zijn biotechnologische activiteiten.

In het derde kwartaal van dit jaar steeg de nettowinst met 9% tot EUR1,85 miljard, terwijl de omzet 4,4% hoger uitkwam op EUR7,03 miljard.

De medicijnontwikkelaar profiteerde van sterke verkopen van vaccinaties en het bloedverdunnende medicijn Plavix. Wel werden de resultaten gedrukt door de sterke euro en de komst van goedkopere varianten op een aantal oudere medicijnen waarvan het patent is verlopen.

Uitgezonderd deze concurrentie van goedkopere medicijnvarianten zou de omzet uit de 15 belangrijkste producten van Sanofi-Aventis met 10,8% zijn gegroeid in het derde kwartaal, aldus het bedrijf.

Door Laetitia Bachelot-Fontaine en Marjolein Timmer; Dow Jones Nieuwsdienst; +31-20-5890270

voda 31 oktober 2007 18:19

0

Devgen rondt deal Indiase zaadactiviteiten Monsanto af

AMSTERDAM (Dow Jones)--Devgen nv heeft de aankoop van een aantal zaadactiviteiten van Monsanto in India afgerond. Monsanto heeft ingetekend op Devgen aandelen. Dit meldt Devgen woensdag nabeurs.

Het Belgische biotechbedrijf koopt Monsanto's hybride rijst, zonnebloem, sorghum en parelgierst activiteiten. De aankoop werd op 14 september aangekondigd.

Monsanto heeft ingetekend op 1.045.400 Devgen-aandelen voor EUR17,22 per aandeel. Hiermee krijgt Monsanto 5,9% van de uitstaande aandelen Devgen in handen.

Door Inger Kuin; Dow Jones Nieuwsdienst; +31-20-5890270; inger.kuin@dowjones.com

[verwijderd] 1 november 2007 14:39

0

RTRS-Winst farmaceut AstraZeneca omlaag
LONDEN (ANP) - De Brits-Zweedse farmaceut AstraZeneca heeft
in het derde kwartaal van dit jaar een winstval gemaakt van 14
procent. De winst voor belastingen bedroeg 1,89 miljard dollar,
1,31 miljard euro. De terugval was minder groot dan analisten
hadden verwacht.

De omzet van de onderneming steeg wel, met 10 procent naar
7,15 miljard dollar (4,9 miljard euro ). Het aandeel AstraZeneca
op de beurs in Londen daalde donderdagmiddag met 2,2 procent in
waarde.

Het farmaceutische bedrijf kampte met sterke concurrentie
van generieke medicijnen, medicijnen waar geen patent meer op
rust en die tegen lagere kosten kunnen worden geproduceerd. Ook
kreeg AstraZeneca te maken met kosten voor een herstructurering.

((ANP Redactie Economie, email economie(at)anp.nl, +31 20
504 5999))

[verwijderd] 5 november 2007 09:47

0

AMT lijdt verlies EUR 8,6 mln in eerste halfjaar--2

Amsterdam Molecular Therapeutics
8,10 ( 09:00 ) -0,37 / -4,37%

toevoeging: extra informatie in gehele artikel naar aanleiding van conference call AMT

Amsterdam (BETTEN BEURSMEDIA NEWS) - Biotechnologiebedrijf Amsterdam Molecular Therapeutics (AMT) heeft in het eerste halfjaar van 2007 een nettoverlies geleden van EUR 8,6 miljoen, tegen EUR 3,2 miljoen in dezelfde periode een jaar eerder. Dat heeft het bedrijf, dat in juni een notering kreeg aan Euronext Amsterdam, woensdag voorbeurs bekendgemaakt.

Tijdens een telefonische toelichting op de halfjaarcijfers gaf bestuursvoorzitter Ronald Lorijn aan dat AMT in ieder geval tot eind 2008 verlieslatend zal blijven. Hij wilde geen winstverwachting geven over de periode erna, maar liet wel weten dat hij verwacht dat vanaf 2009 omzet zal worden gegenereerd. In dat jaar denkt AMT zijn belangrijkste product AMT-011 op de markt te brengen.

AMT, dat gentherapieen ontwikkelt voor zeldzame ziektes waarvoor nog geen behandelingswijze is, zag het operationele verlies het eerste halfjaar oplopen van EUR 4,2 miljoen naar EUR 7,2 miljoen. Dit was met name te wijten aan een toename van R&D-kosten, deze stegen het afgelopen halfjaar naar EUR 3,8 miljoen, tegen EUR 1,9 miljoen in dezelfde periode een jaar eerder.

Volgens financieel-directeur Andre Verweij van AMT is het onwaarschijnlijk dat de kosten in verband met research & development even hoog zullen uitkomen in het tweede halfjaar, aangezien er in de eerste zes maanden enkele eenmalige kosten werden geboekt die zich niet zullen herhalen in de tweede helft van 2007.

De toegenomen kosten hebben vooral betrekking op de ontwikkeling van AMT's belangrijkste product op dit moment, AMT-011, een middel om een ernstige en zeldzame metabolische afwijking mee te bestrijden. Bij deze patienten wordt het enzym LPL niet geproduceerd in de spieren, waardoor vetophopingen in het lichaam ontstaan. Dit lijdt vaak tot ontsteking van de alvleesklier, waaraan vervolgens 30-40% van de patienten lijdt.

Tussen de 6.000 en 8.000 mensen in de 'westerse landen' lijden aan de ziekte. AMT-011 zit momenteel in de klinische pre-registratiestudie. In 2008 wordt naar verwachting een registratieverzoek ingediend en uiteindelijk hoopt AMT dit product in 2009 op de markt zetten, eerst in Europa, en later in de Verenigde Staten en Canada.

Naast toegenomen R&D-kosten, werd het biotechnologiebedrijf dat in 1998 werd opgericht door enkele onderzoekers van het AMC-ziekenhuis geconfronteerd met gestegen kosten in verband met uitbreiding van het personeelsbestand.

De kaspositie van AMT bedroeg 30 juni 2007 EUR 56,3 miljoen, vergeleken met EUR 14,1 miljoen op 31 december 2006. CFO Verweij gaf aan dat de cashburn van AMT gemiddeld genomen zo'n EUR 1 miljoen bedraagt. Dit jaar wordt dit echter sterk beinvloed door kosten in verband met de beursgang van AMT. De omzet van AMT kwam over het eerste halfjaar uit op EUR 50.000, tegen EUR 208.000 een jaar eerder.

AMT laat woensdag weten dat een exclusieve licentie heeft gekregen om alle gentherapieproducten te commercialiseren die afkomstig zijn van het Center for the Study of Applied Medicine (CIMA), dat verbonden is aan de universiteit van Navarra in Spanje. Dit is volgens Lorijn internationaal gezien een van de meest gerenommeerde academische onderzoeksinstituten op het gebied van gentherapie.

Carolien Terlien
carolien@bfn.com

(c) BETTEN BEURSMEDIA NEWS (tel: +31 20 710 1756; fax: +31 20 710 1875)

Vertraagd	12 feb 2025 17:35
Koers	0,842
Verschil	0,000 (0,00%)
Hoog	0,851
Laag	0,835
Volume	2.259.723
Volume gemiddeld	5.423.004
Volume gisteren	2.259.723

07 feb	Pharming verklaart bod op Abliva onvo...
21 jan	Pharming stemt over nieuwe CEO
21 jan	Pharming presenteert nieuwe CEO
16 jan	Fundlogic verkoopt bijna geheel belan...	4
15 jan	Fundlogic flink groter in Pharming	1
07 jan	DWS meldt groter belang in Pharming
31 dec	Morgan Stanley groter in Pharming
23 dec	CEO: Pharming koopt met KL1333 van Ab...
19 dec	RBC verhoogt koersdoel Pharming fors
16 dec	Afwachtend begin van Super Central Ba...

Pharming « Terug naar discussie overzicht

Sectornieuws - biotech

Meedoen aan de discussie?

Direct naar Forum

Detail

Pharming nieuws